A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
Active, not recruiting · NCT04757363 · Registry updated 2026-03-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal disorder, neoplasm | Active, not recruiting | Phase 2 | 2026-03-04 | NCT04757363 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bayer | 178 |
| Bristol-Myers Squibb | 422 |
| Memorial Sloan Kettering Cancer Center | 753 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge (All Protocol Activities) | Basking Ridge | United States | 56 |
| Memorial Sloan Kettering Bergen (All Protocol Activities) | Montvale | United States | 82 |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York | United States | 230 |
| Memorial Sloan Kettering Commack (All Protocol Activities) | Commack | United States | 20 |
| Memorial Sloan Kettering Monmouth (All Protocol Activities) | Middletown | United States | 92 |
| Memorial Sloan Kettering Nassau (All Protocol Activities) | Uniondale | United States | 53 |
| Memorial Sloan Kettering Westchester (All Protocol Activities) | Harrison | United States | 86 |